Congenital disorder of glycosylation caused by mutation in ALG6 is a rare inherited disease. It happens when both copies of a gene called ALG6 do not work well. The ALG6 gene makes an enzyme (a worker-protein) that helps attach tiny sugar chains to other proteins inside our cells. This sugar-adding process is called glycosylation. It takes place mainly in a cell part called the endoplasmic reticulum. The ALG6 enzyme’s job is to add the first glucose sugar onto a growing sugar chain that sits on a small lipid “handle” (a dolichol-linked oligosaccharide). If ALG6 does not work, the sugar chain is built the wrong way. Many proteins then do not fold or travel correctly. Because many organs need glycosylated proteins, many body systems can be affected. MedlinePlus+2NCBI+2

ALG6-CDG is a rare, inherited disease that affects how the body adds sugar chains to many proteins and fats. This sugar-adding process is called N-linked glycosylation. In ALG6-CDG, both copies of a gene named ALG6 are changed (mutated). The ALG6 gene normally makes an enzyme that adds the very first glucose (a sugar) onto a growing sugar chain inside the endoplasmic reticulum of cells. When ALG6 does not work well, many proteins are built with the wrong sugars or with missing sugars. These faulty proteins cannot fold, travel, or work properly. Because glycosylation touches almost every organ, symptoms can involve the brain, muscles, liver, eyes, heart, growth, blood clotting, and digestion. ALG6-CDG used to be called CDG type Ic. It is autosomal recessive, meaning a child gets one non-working ALG6 gene from each parent. There is no approved cure today; care focuses on treating symptoms and preventing complications. CDG Hub+3MedlinePlus+3virtualglycome.org+3

ALG6-CDG follows an autosomal recessive pattern. This means a child is affected when they receive one non-working ALG6 gene from each parent. Carriers (parents with one non-working copy) usually have no symptoms. MedlinePlus

Doctors consider ALG6-CDG one of the more common CDG (congenital disorders of glycosylation) types, though it is still very rare. Reported patients are in the dozens worldwide, and numbers have risen as genetic testing improves. NCBI

Typical problems include low muscle tone in infancy (hypotonia), delayed development, problems with balance (ataxia), and seizures. Some people also have vision problems such as misaligned eyes (strabismus) or slowly worsening retinal changes. Girls and women can have hormone problems (hypergonadotropic hypogonadism) and may not go through puberty in the usual way. The severity can vary from mild to moderate, and some features seen in other CDG types (like stroke-like episodes) are uncommon or not typical in ALG6-CDG. MedlinePlus+2PubMed+2

Other names

This condition has several names in medical writing. You may see: ALG6-CDG, congenital disorder of glycosylation type Ic, CDG-Ic, CDG1C, carbohydrate-deficient glycoprotein syndrome type Ic (older name), carbohydrate-deficient glycoprotein syndrome type V (historical), and glucosyltransferase 1 deficiency. All point to the same disease due to changes in the ALG6 gene. MedlinePlus

Types

Doctors do not split ALG6-CDG into strict official subtypes. Instead, they describe a spectrum:

Neurologic-predominant form. Infants or children have low muscle tone, slower milestones, ataxia, and often epilepsy. Many fit this pattern. Brain scans may show a thin corpus callosum or mild brain/cerebellar atrophy. PubMed+1

Multisystem form. In addition to neurologic signs, some people have feeding problems, poor growth, bleeding issues (clotting factor changes), eye problems (strabismus or retinal degeneration), and female puberty/hormone problems. MedlinePlus

Milder/attenuated form. Some persons have milder learning issues and balance problems without severe complications. On average, ALG6-CDG is often milder than the most common CDG (PMM2-CDG). NCBI

These “types” simply reflect how widely symptoms can vary from person to person.

Causes

For a rare genetic disease like ALG6-CDG, “causes” really means the genetic and biological reasons the disease appears or looks different between people. Here are 20 plain-language causes or contributors:

1. Biallelic ALG6 mutations. The core cause is having disease-causing variants in both ALG6 gene copies (one from each parent). This stops normal enzyme work. MedlinePlus

2. Loss-of-function variants. Some changes delete or break the gene so the enzyme is missing or inactive. MedlinePlus

3. Missense variants. A single “letter” change swaps one amino acid for another and weakens the enzyme. A well-known example is p.Ala333Val (A333V). MedlinePlus

4. Splice-site variants. Changes near intron–exon borders can derail RNA splicing. A known example is c.257+5G>A. NCBI

5. Compound heterozygosity. One damaging variant on each copy (two different variants) can combine to cause disease. PMC

6. Homozygosity for a pathogenic variant. The same harmful variant on both copies can cause a typical picture. A333V has been seen in homozygous form. PubMed

7. Common/frequent variants in ALG6. Some variants occur more often in certain populations (founder effects), shaping who is diagnosed. PubMed

8. Enzyme step failure. ALG6 specifically adds the first glucose to the lipid-linked oligosaccharide. When this step fails, the early N-glycan “scaffold” is wrong. virtualglycome.org

9. Protein misfolding and ER stress. Poor glycosylation can make proteins misfold and stress the endoplasmic reticulum, disturbing cell health. (Mechanism widely recognized in N-glycosylation disorders.) BioMed Central

10. Global glycoprotein dysfunction. Many cell receptors, clotting factors, hormones, and transport proteins rely on N-glycans; their dysfunction leads to multi-organ signs. MedlinePlus

11. Autosomal recessive inheritance. Family patterns (including consanguinity) raise the chance that both parents carry a variant. MedlinePlus

12. Modifier genes. Variants in other glycosylation genes can change severity in some CDG families (shown in broader CDG literature). BioMed Central

13. Variant-specific effects. Some ALG6 changes (e.g., A333V, p.I299del) are linked to recognizable clinical patterns. PubMed

14. Tissue expression needs. Organs with heavy glycoprotein traffic (brain, eyes, liver, endocrine system) show more symptoms. MedlinePlus

15. Developmental timing. Early brain and eye development are sensitive to glycosylation problems, so infancy signs are common. MedlinePlus

16. Coagulation factor under-glycosylation. Abnormal N-glycans on clotting proteins can cause bleeding or clotting problems in CDG. MedlinePlus

17. Hormone receptor changes. Glycosylation affects hormone signaling; this may underlie female hypogonadism in ALG6-CDG. MedlinePlus

18. Neuronal network instability. Under-glycosylated synaptic proteins can increase seizure risk. (Shown broadly in CDG reviews.) ScienceDirect

19. Population genetics and founder variants. Certain groups may share older variants passed through generations, influencing local case numbers. PubMed

20. Diagnostic access. Wider use of transferrin testing and exome/genome sequencing increases detection; earlier under-recognition is part of why the disease seems rare. CDG Hub

Symptoms

Symptoms vary. Not every person has every sign. Here are common and reported features in easy words:

Hypotonia (low muscle tone) in infancy. Babies may feel “floppy,” have weak head control, and feed slowly. This is very common. PubMed

Developmental delay. Sitting, standing, walking, and speech may come later than usual. Learning support is often needed. MedlinePlus

Ataxia (balance and coordination problems). Children may be unsteady, have wide-based gait, or trouble with fine finger control. PubMed

Seizures. Seizures can start in infancy or childhood and may need long-term care. EEG helps guide treatment. PubMed

Feeding problems and poor weight gain. Many infants have trouble feeding and gaining weight (failure to thrive). MedlinePlus

Eye misalignment (strabismus). Eyes may not point the same way. Vision tracking can be weak. MedlinePlus

Retinal changes. Some people develop retinitis pigmentosa, which can slowly reduce vision. This is not in everyone. MedlinePlus

Clotting problems. Easy bruising or other clotting changes can occur because some clotting proteins are under-glycosylated. MedlinePlus

Puberty and hormone issues in females. Many girls with ALG6-CDG have hypergonadotropic hypogonadism and may not start puberty normally. MedlinePlus

Behavior or attention concerns. Some families report behavior changes or attention problems along with learning issues. (Described in ALG6 cohorts.) PubMed

Thin corpus callosum or mild brain/cerebellar atrophy on MRI. These are scan findings, not things a person feels, but they help explain balance and tone problems. Wiley Online Library

Proximal muscle weakness. Thigh and shoulder muscles may be weaker, making stairs or lifting harder. PubMed

Head control delay and poor trunk stability. Part of the hypotonia picture in babies and toddlers. PubMed

Stroke-like episodes. These are common in some other CDGs, but for ALG6-CDG they are uncommon and have been historically not reported; summaries differ. Doctors judge case by case. NCBI+1

Rare features. A few reports mention deep vein thrombosis, brachydactyly, pseudotumor cerebri, and pubertal abnormalities; these are not common but have been observed. NCBI

Diagnostic tests

A) Physical examination (at the bedside)

1. General growth check. The doctor measures weight, length/height, and head size over time. Poor weight gain or short stature may be seen in infancy. MedlinePlus

2. Neurologic tone and reflex exam. The doctor checks low tone, reflexes, and posture. Hypotonia is common and guides therapy plans. PubMed

3. Gait and balance observation. Watching how a child sits, stands, and walks can show ataxia or wide-based gait and the need for physical therapy. PubMed

4. Eye alignment and tracking. Bedside tests (cover–uncover, fixation) screen for strabismus and vision concerns. MedlinePlus

5. Puberty staging (girls). Doctors check for normal timing of breast and menstrual development because hypergonadotropic hypogonadism is reported in females with ALG6-CDG. MedlinePlus

B) Manual/bedside functional tests

6. Developmental screening. Tools like Bayley scales or simple milestone checklists measure motor and language progress and help plan therapies. (Standard pediatric practice.)

7. Coordination tests. Finger-to-nose, heel-to-shin, rapid alternating movements, and tandem (heel-to-toe) walking help rate ataxia and fine motor control. (Standard neurologic exam.)

8. Feeding and swallow assessment. A structured feeding review by speech-language therapy checks sucking, chewing, and risk of aspiration given early feeding problems. MedlinePlus

9. Vision function tests. Visual acuity and visual field checks help track retinal involvement. If needed, retina specialists add electroretinography (see below). MedlinePlus

10. Physiotherapy evaluation. A therapist grades trunk and proximal muscle strength (sit-to-stand time, stair climbing) to tailor exercise plans. PubMed

C) Laboratory & pathology tests

11. Serum transferrin glycoform analysis. This is the key screening test for N-glycosylation CDGs. It uses isoelectric focusing or mass-spec to look for a type I pattern (reduced fully glycosylated transferrin with more under-glycosylated forms), which fits ALG6-CDG and other early-pathway CDGs. PMC+1

12. Molecular genetic testing of ALG6. Sequencing finds the exact variants. Known pathogenic changes include A333V, c.257+5G>A, and others. This confirms the diagnosis. MedlinePlus+1

13. Coagulation studies. PT/INR, aPTT, and specific clotting factor levels can be abnormal in CDG and explain bruising or bleeding. MedlinePlus

14. Liver enzymes and function tests. AST/ALT and other markers may be checked, since the liver handles many glycoproteins. (Standard CDG work-up.) Frontiers

15. Endocrine testing (girls). LH, FSH, estradiol help document hypergonadotropic hypogonadism in females with delayed puberty. MedlinePlus

D) Electrodiagnostic tests

16. EEG (electroencephalogram). EEG documents seizure type and guides anti-seizure treatment planning; epilepsy is frequent in ALG6-CDG series. PubMed

17. Electroretinography (ERG) when needed. ERG measures retinal function if retinitis pigmentosa is suspected, helping track vision changes over time. MedlinePlus

18. Evoked potentials (as indicated). Visual evoked potentials can complement ERG and MRI findings in complex neurologic cases. (Used variably in CDG evaluations.) PMC

E) Imaging tests

19. Brain MRI. MRI may show thin corpus callosum and mild cerebral or cerebellar atrophy in some patients, supporting the neurologic picture. Wiley Online Library

20. Eye imaging (OCT) and specialist exam. Optical coherence tomography and dilated eye exams document retinal layer changes when vision symptoms are present. (Standard ophthalmic practice in retinal disease; linked to retinopathy in ALG6-CDG.) MedlinePlus

Non-pharmacological (non-drug) treatments

(each with description, purpose, mechanism; customize with your clinical team)

1. Physiotherapy for hypotonia and ataxia – Regular guided exercises improve posture, trunk control, balance, and walking by strengthening muscles and training the brain’s motor pathways (neuroplasticity). Purpose: reduce falls, improve mobility, prevent contractures. Mechanism: task-specific motor learning and graded strengthening. PMC

2. Occupational therapy (OT) – Trains daily living skills (feeding, dressing, fine motor tasks) and adapts the home or school setup. Purpose: independence and safety. Mechanism: activity analysis, assistive strategies, and adaptive tools. PMC

3. Speech-language therapy – Supports speech clarity, language, and safe swallowing. Purpose: communication and aspiration prevention. Mechanism: oropharyngeal muscle training and language enrichment. PMC

4. Feeding and swallowing therapy – Thickened feeds, pacing, and posture reduce choking and improve intake. Purpose: better nutrition and growth. Mechanism: compensatory swallow techniques and texture modification. PMC

5. Nutrition plan with calorie optimization – High-calorie, nutrient-dense meals; consider MCT oils if fat absorption is poor. Purpose: address failure to thrive. Mechanism: energy density and easier fat absorption. PMC

6. Low-vision rehabilitation / strabismus optics – Prisms, patching, or low-vision aids. Purpose: maximize visual function. Mechanism: optical correction and visual neuro-adaptation. MedlinePlus

7. Audiology care and hearing devices (if needed) – Early amplification improves language acquisition. Purpose: better hearing and speech. Mechanism: sound amplification and auditory training. Frontiers in Glycosylation

8. Seizure safety education – First-aid training, water safety, and rescue plan. Purpose: lower injury risk and anxiety. Mechanism: preparedness for seizure events. MedlinePlus

9. Sleep hygiene program – Fixed sleep/wake times, light control, and calming routines. Purpose: reduce insomnia and daytime fatigue. Mechanism: circadian entrainment and arousal control. PMC

10. Behavioral therapy (ABA/CBA-informed as appropriate) – Addresses attention, behavior, or sensory needs. Purpose: smoother home and school life. Mechanism: reinforcement and coping strategies. PMC

11. Early intervention / special education plans – Individualized learning goals with therapies embedded in school. Purpose: maximize cognitive progress. Mechanism: structured, repetitive skill-building. PMC

12. Orthotics and mobility aids – Ankle-foot orthoses, walkers, or wheelchairs, as needed. Purpose: safer, more efficient movement. Mechanism: mechanical alignment and energy conservation. PMC

13. Respiratory therapy (if weak cough) – Chest physiotherapy, airway clearance devices. Purpose: reduce infections and atelectasis. Mechanism: improved mucus clearance. PMC

14. Social work & care coordination – Links families with services, equipment, and respite care. Purpose: reduce caregiver strain. Mechanism: navigation of resources.

15. Genetic counseling – Explains inheritance, testing, and options for future pregnancies (carrier testing, prenatal diagnosis, IVF with PGT). Purpose: informed family planning. Mechanism: risk assessment and counseling. NCBI

16. Regular dental and oral-motor care – Positioning, fluoride, and oral-motor exercises. Purpose: prevent caries and improve feeding mechanics. Mechanism: hygiene and muscular training.

17. Vision protection and sun safety – UV-blocking lenses for retinal issues. Purpose: eye comfort and potential protection. Mechanism: light filtering. MedlinePlus

18. Developmental “just-right challenge” home program – Short, daily practice of targeted skills. Purpose: generalization of therapy gains. Mechanism: spaced repetition.

19. Vaccination on schedule – Routine immunizations unless your doctor advises otherwise. Purpose: prevent infections that can worsen health. Mechanism: immune priming.

20. Family and mental-health support – Counseling or peer groups for family resilience. Purpose: reduce stress and burnout. Mechanism: coping skills and community.

Drug treatments

Important: There is no disease-modifying drug approved for ALG6-CDG. Medicines below are standard symptomatic options used in CDG care when those problems exist. Doses must be individualized by a clinician; examples are typical pediatric ranges where well-established. CDG Hub

1. Levetiracetam (antiepileptic). Usual pediatric goal range ~20–60 mg/kg/day in 2 doses. Purpose: control seizures. Mechanism: SV2A modulation reduces neuronal hyperexcitability. Side effects: irritability, somnolence. (General epilepsy practice.)

2. Valproate (antiepileptic; caution with liver disease). ~10–60 mg/kg/day in divided doses; monitor liver tests and ammonia. Purpose: broad-spectrum seizure control. Mechanism: GABA increase and sodium channel effects. Side effects: hepatotoxicity risk, weight gain, thrombocytopenia, teratogenicity. (General epilepsy practice; use carefully if hepatic issues are present.)

3. Clobazam (benzodiazepine adjunct). ~0.25–1 mg/kg/day. Purpose: add-on for refractory seizures. Mechanism: GABA-A modulation. Side effects: sedation, tolerance.

4. Topiramate (antiepileptic). ~3–9 mg/kg/day. Purpose: seizures and sometimes migraine prevention. Mechanism: multiple ion channel effects. Side effects: cognitive slowing, weight loss.

5. Melatonin (sleep). 1–5 mg at bedtime. Purpose: improve sleep onset/maintenance. Mechanism: circadian signaling. Side effects: morning grogginess.

6. Baclofen (spasticity). Start low, titrate (e.g., 0.3–0.75 mg/kg/day divided). Purpose: reduce muscle stiffness/spasms. Mechanism: GABA-B agonist. Side effects: sedation, weakness.

7. Proton-pump inhibitor (e.g., omeprazole) for reflux. Pediatric dosing per weight (e.g., 0.7–3.5 mg/kg/day). Purpose: protect esophagus, reduce pain. Mechanism: blocks acid production. Side effects: diarrhea, low magnesium with long use.

8. Prokinetic trial (specialist-guided) such as erythromycin low-dose for gastroparesis. Purpose: help stomach emptying. Mechanism: motilin receptor effect. Side effects: GI upset, QT risk; use with ECG caution.

9. Stool softener or osmotic laxative (e.g., polyethylene glycol). Titrated to effect. Purpose: treat constipation from hypotonia or meds. Mechanism: water retention in stool. Side effects: bloating.

10. Antiemetic (ondansetron) for severe vomiting. Weight-based dosing. Purpose: reduce nausea. Mechanism: 5-HT3 blockade. Side effects: constipation, QT risk.

11. Ursodeoxycholic acid (if cholestasis). ~10–30 mg/kg/day. Purpose: improve bile flow and pruritus. Mechanism: hydrophilic bile acid replacement. Side effects: diarrhea.

12. Fat-soluble vitamins A, D, E, K (if liver disease or malabsorption). Doses per deficiency labs. Purpose: prevent deficiency complications (vision, bone health, bleeding). Mechanism: replacement. Side effects: hypervitaminosis if overdosed. PMC

13. Vitamin K (if coagulopathy/low factors). Dosing per hematology. Purpose: improve clotting. Mechanism: cofactor for clotting factor carboxylation. Side effects: rare allergy with IV. MedlinePlus

14. Fibrinogen concentrate or other factor support for significant bleeding risk as guided by hematology. Purpose: correct low clotting proteins. Mechanism: replaces missing factors. Side effects: thrombosis risk; monitor. PMC

15. Heparin (specialist-directed) has been used in CDG patients with protein-losing enteropathy or thrombosis; decision is individualized. Purpose: reduce clotting/PLE. Mechanism: antithrombin-mediated anticoagulation; PLE mechanism may involve lymphatic flow. Side effects: bleeding risk. (Evidence mainly from other CDG types; consider risks/benefits.) PMC

16. ACE inhibitor or beta-blocker (if cardiomyopathy is present). Dosing per cardiology. Purpose: support heart function. Mechanism: neurohormonal blockade. Side effects: hypotension, bradycardia. PMC

17. Pancreatic enzyme replacement if exocrine pancreatic insufficiency is documented. Purpose: better fat/protein absorption. Mechanism: enzyme replacement. Side effects: perianal irritation, rare fibrosing colonopathy. PMC

18. Salt supplementation / fludrocortisone only if documented orthostatic hypotension or dysautonomia, under specialist care. Purpose: reduce dizziness. Mechanism: expands plasma volume. Side effects: hypertension, low potassium.

19. Antipruritic agents (e.g., cholestyramine, hydroxyzine) for itching due to cholestasis. Purpose: comfort. Mechanism: bile acid binding or H1 antagonism. Side effects: constipation, sedation.

20. Rescue benzodiazepine (e.g., intranasal midazolam) per seizure plan. Purpose: stop prolonged seizures. Mechanism: GABA-A potentiation. Side effects: sedation, respiratory depression—use only as prescribed.

---

Dietary / molecular supplements

(use if indicated by your clinician; monitor levels and interactions)

1. L-carnitine (e.g., 50–100 mg/kg/day). Supports fatty-acid transport into mitochondria; may help energy and reduce fatigue if low.

2. Coenzyme Q10 (e.g., 5–10 mg/kg/day). Electron-transport cofactor; antioxidant; sometimes used for neuromuscular symptoms.

3. Omega-3 (EPA/DHA) (weight-based). Anti-inflammatory; may support neurodevelopment and heart health.

4. MCT oil (measured by dietitian). Easier-to-absorb fats for poor fat absorption or cholestasis.

5. Vitamin D (dose per level). Bone health and immunity; correct deficiency.

6. Vitamin E (dose per level). Antioxidant; prevents deficiency neuropathy in cholestasis.

7. Vitamin A (dose per level). Vision and epithelial health (avoid excess).

8. Vitamin K (dose per INR/level). Clotting support when low.

9. Zinc (dose per level). Supports growth and immune function when deficient.

10. Probiotics (strain/dose per pediatric GI). May reduce constipation or antibiotic-associated diarrhea. (These are supportive; none fix the core glycosylation defect.) PMC

---

Regenerative / stem-cell drugs

There are no approved immune-booster drugs, stem-cell drugs, or gene therapies for ALG6-CDG. Research directions for CDG broadly include: (1) gene-specific therapies (AAV or mRNA), (2) pharmacologic chaperones to stabilize mutant enzymes, (3) substrate supplementation for select CDGs (e.g., mannose for MPI-CDG, galactose for PGM1-CDG) but not effective for ALG6-CDG, and (4) pathway-wide small molecules. These remain experimental and must be done in clinical trials. Do not use unregulated “stem-cell” products. If you are interested in trials, ask your clinician to check CDG registries and academic centers. CDG Hub+1

---

Surgeries and procedures

1. Gastrostomy tube (G-tube/PEG) – For unsafe swallowing or poor growth despite intensive feeding therapy. Why: secure long-term nutrition and reduce aspiration.

2. Strabismus surgery – For significant eye misalignment that persists despite glasses/therapy. Why: improve eye alignment and potential binocular vision. MedlinePlus

3. Orthopedic tendon-lengthening or contracture release – For fixed deformities limiting care or mobility. Why: improve positioning, hygiene, and comfort.

4. Scoliosis instrumentation (in select cases). Why: correct severe curvature affecting sitting, care, or breathing.

5. Cochlear implant (if severe sensorineural hearing loss). Why: improve access to sound and language. Frontiers in Glycosylation

---

Prevention and safety strategies

1. Genetic counseling for carriers and future pregnancies (carrier testing, prenatal testing, IVF with PGT).

2. Vaccinations on schedule to reduce infection-related setbacks.

3. Seizure plan and water safety to prevent injury.

4. Nutrition monitoring with early dietitian input to prevent malnutrition.

5. Fall prevention at home and school; use mobility aids correctly.

6. Dental and swallowing checks to prevent aspiration and pneumonia.

7. Skin care and pressure relief for those with low mobility.

8. Medication reconciliation to avoid liver-toxic or sedation-heavy combinations if liver disease or seizures exist.

9. Regular vision/hearing checks to catch problems early.

10. Family support and respite to prevent caregiver burnout.

---

When to see a doctor urgently

• New or worsening seizures, a seizure lasting >5 minutes, or repeated seizures without full recovery.

• Signs of aspiration: choking, coughing with feeds, blue lips, fast breathing.

• Severe dehydration from vomiting/diarrhea or very poor intake.

• Unusual bleeding or bruising, or very dark/tarry stools.

• Yellow eyes/skin, swelling of belly, severe itch (possible liver issues).

• Sudden weakness, new trouble walking or speaking, dramatic change in alertness.

• Chest pain, fainting, shortness of breath, or fast/irregular heartbeat. (Call emergency services for life-threatening symptoms.)

---

Living with ALG6-CDG: daily care notes

• Build a multidisciplinary team (pediatrics, neurology, genetics, gastroenterology, nutrition, physiatry, ophthalmology, audiology, cardiology as needed).

• Keep a written care plan: seizure rescue steps, feeding plan, therapy goals, and emergency contacts.

• Track growth and labs every 3–6 months (or as advised).

• Use therapies early and consistently; small daily practice adds up.

• Re-check hearing/vision yearly or sooner if concerns arise.

---

Diet: eat / avoid” tips

What to eat more of:

1. Energy-dense foods (nut butters, oils added to purees, fortified smoothies) to support growth.

2. Balanced protein at each meal to maintain muscle strength.

3. Complex carbs and fiber to support steady energy and bowel regularity.

4. Fluids throughout the day to prevent dehydration and constipation.

5. If fat absorption is reduced, consider MCT oil or specialized formulas (dietitian-guided). PMC

What to limit or avoid:

1.  Foods that are difficult to chew/swallow (nuts, tough meats) unless texture-modified.
2. Highly acidic or spicy foods if reflux is a problem.
3. Sugary drinks that displace nutritious calories.
4. Unpasteurized or high-risk foods if frequent infections or aspiration risk exist.
5.  Alcohol and sedating over-the-counter drugs in older teens/adults (can worsen coordination or interact with meds).

---

FAQs

1) Is ALG6-CDG curable?
No. There is no approved cure right now. Treatment focuses on symptoms and complication prevention. Research is ongoing. CDG Hub

2) How is it inherited?
Autosomal recessive: both parents are usually healthy carriers; each pregnancy has a 25% chance to be affected. NCBI

3) What organs can be affected?
Brain, muscles, eyes, liver, blood clotting, gut, and sometimes the heart. Symptoms vary by person. MedlinePlus+1

4) Is it milder than PMM2-CDG?
Often, but not always. ALG6-CDG tends to have a milder course overall, yet individual severity differs. NCBI

5) What tests confirm it?
Abnormal transferrin glycoform screen plus genetic testing that finds pathogenic variants in ALG6. PMC+1

6) Can diet alone fix the problem?
No. Diet supports growth and comfort but does not correct the glycosylation defect. PMC

7) Are mannose or galactose therapies helpful?
They help specific other CDGs (like MPI-CDG or PGM1-CDG), not ALG6-CDG. PMC

8) What about stem cells or gene therapy now?
Not available for ALG6-CDG outside research. Avoid unregulated clinics. CDG Hub

9) Will my child walk or talk?
Many children gain skills with therapy; timing and degree vary. Early, intensive, and playful practice helps. PMC

10) Do children outgrow seizures?
Some improve; others need long-term medication. A pediatric neurologist will tailor care. MedlinePlus

11) Can vision or hearing improve?
Supportive care (glasses, therapy, devices, or surgery) often helps function. MedlinePlus+1

12) Is heart disease guaranteed?
No. It is uncommon but reported; your doctor will screen if there are symptoms or exam findings. PMC

13) How often are labs needed?
Typically every 3–6 months at first, then adjusted based on stability and specialist advice. PMC

14) Can adults have ALG6-CDG?
Yes; severity ranges widely. Adult care focuses on function, independence, and monitoring. NCBI

15) Where can families learn more or find studies?
CDG-focused hubs, rare disease networks, and genetics clinics can share updates and registries. Frontiers in Glycosylation+1

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 12, 2025.